Acquisition

Five things for pharma marketers to know: Friday, February 16, 2018

Five things for pharma marketers to know: Friday, February 16, 2018

Roche to acquire Flatiron Health for $1.9B; FDA considers allowing pre-symptom Alzheimer's drug tests; Marijuana producer branches into pharma.

Capgemini expands digital chops with LiquidHub acquisition

Capgemini expands digital chops with LiquidHub acquisition

By

LiquidHub formed a health- and life-sciences-focused offering last June after acquiring Eveo.

Omnicom Health acquires Snow Companies

Omnicom Health acquires Snow Companies

Snow Companies, which emphasizes patient storytelling, was founded by Brenda Snow in 2001.

Five things for pharma marketers to know: Monday, January 22, 2018

Five things for pharma marketers to know: Monday, January 22, 2018

By

Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia

Five things for pharma marketers to know: Wednesday, January 17, 2018

Five things for pharma marketers to know: Wednesday, January 17, 2018

By

Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

By

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Stagwell's Penn says digital marketing agencies are 'undervalued' as he eyes more M&A

Stagwell's Penn says digital marketing agencies are 'undervalued' as he eyes more M&A

By

The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.

Five things for pharma marketers to know: Wednesday, January 10, 2018

Five things for pharma marketers to know: Wednesday, January 10, 2018

By

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Five things for pharma marketers to know: Monday, January 8, 2018

By

Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO

The buyer's guide to pharma, healthcare, and life sciences consultancies

The buyer's guide to pharma, healthcare, and life sciences consultancies

By

Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Wednesday, December 27, 2017

Five things for pharma marketers to know: Wednesday, December 27, 2017

By

Mallinckrodt to buy Sucampo for $1.2 billion; Amazon pushes digital advertising in 2018; WHO classifies gaming disorder as mental health condition

Five things for pharma marketers to know: Tuesday, December 26, 2017

Five things for pharma marketers to know: Tuesday, December 26, 2017

By

Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

By

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

Five things for pharma marketers to know: Friday, December 15, 2017

Five things for pharma marketers to know: Friday, December 15, 2017

By

FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns

CVS/Aetna Moves Healthcare M&A Beyond Cost and into Disruption

CVS/Aetna Moves Healthcare M&A Beyond Cost and into Disruption

This time around the M&A moves will be much bigger in scope, promising to reconfigure the complex and fragile healthcare payer/provider/patient ecosystem.

 Five things for pharma marketers to know: Thursday, December 7, 2017

Five things for pharma marketers to know: Thursday, December 7, 2017

By

UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval

Five things for pharma marketers to know: Monday, December 4, 2017

Five things for pharma marketers to know: Monday, December 4, 2017

By

CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate

Five things for pharma marketers to know: Thursday, November 9, 2017

Five things for pharma marketers to know: Thursday, November 9, 2017

By

GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick

UDG Healthcare acquires MicroMass, for up to $75.8 million

UDG Healthcare acquires MicroMass, for up to $75.8 million

By

The company also this year has purchased Vynamic and Cambridge BioMarketing.

Digital Healthcare: Is It For Real?

Digital Healthcare: Is It For Real?

The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

By

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

MM&M's top 5 stories in February 2017

MM&M's top 5 stories in February 2017

By

WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue